Who Paid My Doc
Lee Ocuin
Surgical Oncology Allentown, PA Medical Doctor
NPI 1770769705 CMS profile 812168
1240 S Cedar Crest Blvd Ste 410, Allentown, PA 18103
General payments
$1,669
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Lee Ocuin of Allentown, PA is reported in the CMS Open Payments database as having received $1,669 across 16 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 51st percentile of Surgical Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $1,061 | 5 | |
| 2023 | General | $200 | 3 | |
| 2022 | General | $232 | 6 | |
| 2020 | General | $164 | 1 | |
| 2019 | General | $12 | 1 |
Beside peers
- Lee Ocuin
- Surgical Oncology median
- Middle half of Surgical Oncology
- National median
In program year 2025, general payments to Lee Ocuin were reported at $1,061. Among 1,137 Surgical Oncology profiles paid that year, the median was $288 and the middle half received between $118 and $1,346.
Show as a table
| Year | Lee Ocuin | Surgical Oncology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $12 | $236 | $86–$1,064 | $163 |
| 2020 | $164 | $130 | $47–$648 | $114 |
| 2021 | $0 | $160 | $53–$943 | $132 |
| 2022 | $232 | $199 | $76–$782 | $149 |
| 2023 | $200 | $246 | $95–$854 | $160 |
| 2024 | $0 | $271 | $106–$1,123 | $164 |
| 2025 | $1,061 | $288 | $118–$1,346 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 1 drugPart D claims
16
Drug cost
$53,483
Branded share of claims
100%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Creon Lipase/Protease/Amylase | Brand | 16 | $53,483 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 682 Part D prescribers listed as Surgical Oncology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 43 billing codesPaid by Medicare
$37,257
Medicare patients
65
Services billed
165
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 54% | |
| Cancer | 40% | |
| Ischemic heart disease | 34% | |
| Diabetes | 32% | |
| Depression | 32% | |
| COPD | 23% | |
| Osteoporosis | 20% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
16 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Surgical Oncology in Pennsylvania
Richard Bleicher
Surgical Oncology · Philadelphia, PA
Catherine Carruthers
Surgical Oncology · Southampton, PA
Nestor Esnaola
Surgical Oncology · Philadelphia, PA
Andrea Porpiglia
Surgical Oncology · Philadelphia, PA
William Morano
Surgical Oncology · Wynnewood, PA
Matthew Holtzman
Surgical Oncology · Pittsburgh, PA
Related records
Surgical Oncology in Pennsylvania
Practitioners in the same specialty and state, ranked by reported value.
All Surgical Oncology
Everyone recorded under this specialty, nationwide.
Doctors in Pennsylvania
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.